On March 7, 2025, in Basel, Novartis shareholders approved all the recommendations made by the Board of Directors during the Annual General Meeting (AGM). The meeting was attended by 1,693 shareholders, which accounted for about 57.42% of Novartis's total shares.
Novartis is not worried about the potential increase in tariffs on pharmaceutical imports that U.S. President Donald Trump might introduce, according to the company's Chairman Joerg Reinhardt in an interview released on Thursday.
Join CNBC's Melissa Lee and the Fast Money traders for the last trades of the day.
On February 28, 2025, Novartis revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive recommendation for Fabhalta® (iptacopan). This medication is a first-of-its-kind oral Factor B inhibitor targeting the alternative complement pathway. It is intended for treating adults with C3 glomerulopathy (C3G).
Syngenta, a pesticide company based in Switzerland, announced on Wednesday that it has purchased a collection of natural compounds and genetic materials from the pharmaceutical company Novartis. This acquisition aims to enhance the development of biological methods for crop protection.
Novartis has pledged $7.5 million to the "Blitz the Barriers" campaign, which seeks to increase awareness and promote early testing for prostate cancer in at-risk communities.
The results for the fourth quarter of 2024 were better than anticipated, showing a 16% rise in net sales and a 55% boost in operating income, which supports Novartis' earnings per share growth. The purchase of Anthos Therapeutics and smart investments in research and development reinforce our belief that Novartis is becoming a leader in innovative medicines. With strong free cash flow, a good dividend yield, and ongoing share buybacks, Novartis is a good investment, especially since it is valued lower than its competitors.
Novartis has a strong lineup of drugs and solid finances, with an AA- credit rating, which leads to an expected annual return of 11% by 2027. The company's successful range of popular products and effective cost management resulted in a 15.1% rise in sales and a 29% increase in earnings per share in the fourth quarter of 2024. Additionally, Novartis' shares are currently undervalued by 11%, suggesting a potential total return of 33% by 2027, along with a stable and increasing dividend yield of 3.5%.
Novartis AG (ADR) (NYSE:NVS) has decided to acquire Anthos Therapeutics in a deal that could reach $3.1 billion. The Swiss pharmaceutical company will pay $925 million initially, along with possible milestone payments totaling $2.15 billion.
Novartis has decided to buy Anthos Therapeutics, a company that has created a new type of blood thinner. Anthos was started five years ago with support from the Swiss pharmaceutical company.